Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corp Chairman and CEO Thomas William Burns reported a routine tax-withholding transaction related to equity compensation. On March 13, 2026, 5,212 shares of common stock were withheld by the company at $97.02 per share to satisfy his tax obligations upon vesting and delivery of previously granted restricted stock units.
After this withholding, Burns directly owns 245,252 common shares. He also has indirect ownership through several trusts, including 961,285 shares held through the Burns Family Trust, 238,107 shares through the Burns Annuity Trust, 120,000 shares through the Burns Charitable Remainder Trust, 100,000 shares through the Thomas W. Burns Irrevocable Trust, and 100,000 shares through the Janet M. Burns Irrevocable Trust. Footnotes state that his position also includes 69,929 restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp officer Tomas Navratil reported a proposed sale of 1,031 common shares, with an aggregate market value of $101,027.69 and an approximate sale date of March 16, 2026. The listed acquisition history shows 259 common shares acquired through restricted stock vesting on December 27, 2024, and 772 on January 1, 2025. The notice lists December 15, 2025 as the plan-adoption or instruction date for reliance on Rule 10b5-1.
Glaukos Corp's Chief Development Officer Tomas Navratil reported a small share disposal related to tax withholding. On March 5, 2026, 361 shares of common stock at $112.10 per share were withheld by the company to satisfy his tax obligations upon vesting of previously granted restricted stock units.
After this tax-withholding disposition, Navratil directly holds 76,694 shares of common stock, which includes 41,561 restricted stock units that have not yet vested or been delivered to him.
Glaukos Corp (GKOS) Chairman & CEO Thomas William Burns reported a tax-related share disposition on March 5, 2026. The company withheld 1,098 shares of common stock at $112.10 per share to cover his tax obligations when previously granted restricted stock units vested.
After this withholding, he directly owns 250,464 common shares, which includes 79,828 restricted stock units that have not yet vested or been delivered. He also reports indirect ownership through several Burns family and charitable trusts, including the Burns Family Trust, Burns Annuity Trust, Burns Charitable Remainder Trust, and two irrevocable trusts, each with disclosed share balances as of the same date.
Glaukos Corporation furnished a new Investor Presentation as Exhibit 99.1 to a current report. The company states it may use this March 2026 presentation from time to time in meetings with investors and other stakeholders, and it will be available on the investor page of its website.
The company clarifies that the Investor Presentation and related disclosure under Item 7.01 are being provided under Regulation FD and are not deemed filed under Section 18 of the Exchange Act or incorporated into other securities law filings unless specifically referenced.
Glaukos Corp chairman and CEO Thomas William Burns reported a tax-withholding share disposition related to restricted stock units. On February 24, 2026, 4,059 shares of common stock were withheld by Glaukos at $119.17 per share to satisfy his tax obligations upon RSU vesting.
After this transaction, Burns directly owns 251,562 shares of Glaukos common stock, which the footnotes state include 81,912 unvested restricted stock units. He also reports additional indirect ownership through multiple Burns family-related trusts, each holding separate blocks of Glaukos shares.
Glaukos Corp’s chief development officer, Tomas Navratil, reported a small tax-related share disposition. On the vesting of previously granted restricted stock units, 396 shares of common stock were withheld by the company at $119.17 per share to cover tax obligations. After this withholding, Navratil directly holds 77,055 shares of common stock, including 42,588 restricted stock units that are granted but not yet vested or delivered.
GLAUKOS Corp President and COO Joseph E. Gilliam reported a Form 4 showing a tax-related share disposition tied to vesting equity awards. On this Form 4, 1,057 shares of common stock were withheld by the company at $119.17 per share to satisfy his tax withholding obligations when restricted stock units granted on March 18, 2021 vested and were delivered.
After this tax-withholding disposition, Gilliam directly owned 91,309 shares of GLAUKOS common stock, which includes 60,661 restricted stock units that have not yet vested or been delivered. This reflects an administrative equity and tax event rather than an open-market stock sale.
GLAUKOS Corp director Aimee S. Weisner reported multiple equity transactions in company stock. She exercised a stock option for 15,000 shares of common stock at an exercise price of $24.69 per share, then reported open-market sales totaling 15,000 shares at weighted average prices between $115.69 and $118.56 across several trade blocks. She also reported bona fide gifts of 980 shares from her direct holdings and 980 shares transferred to the Saeman-Weisner Family Trust. After these transactions, she directly owned 18,806 shares and indirectly owned 29,505 shares through the Saeman-Weisner Family Trust, which includes 2,731 restricted stock units noted in the footnotes.